Influence of corticosteroid therapy on IL-18 and nitric oxide production during Behçet's disease.

Autor: Djaballah-Ider F; Universite des Sciences et de la Technologie Houari Boumediene, Algiers, Algeria., Djeraba Z; Universite des Sciences et de la Technologie Houari Boumediene, Algiers, Algeria., Chemli M; Service de Medecine Interne, Hopital Dr Md Seghir NEKKACHE, Algiers, Algeria., Dammene-Debbihe N; Service de Medecine Interne, Hopital Dr Md Seghir NEKKACHE, Algiers, Algeria., Lounis D; Service de Medecine Interne, Hopital Dr Md Seghir NEKKACHE, Algiers, Algeria., Belguendouz H; Universite des Sciences et de la Technologie Houari Boumediene, Algiers, Algeria., Medour Y; Service d'Immunologie, Hopital Dr Md Seghir NEKKACHE, Algiers, Algeria., Chaib S; Service d'Immunologie, Hopital Dr Md Seghir NEKKACHE, Algiers, Algeria., Touil-Boukoffa C; Universite des Sciences et de la Technologie Houari Boumediene, Algiers, Algeria. touilboukoffa@yahoo.fr.
Jazyk: angličtina
Zdroj: Inflammopharmacology [Inflammopharmacology] 2018 Jun; Vol. 26 (3), pp. 725-735. Date of Electronic Publication: 2018 Mar 29.
DOI: 10.1007/s10787-018-0472-2
Abstrakt: Background and Aims: Behçet's disease (BD) is a chronic multisystemic inflammatory disease with complex etiopathogenesis. Th1-proinflammatory cytokines seem to be involved in its pathogenesis. Our current study aims to evaluate interleukin-18 (IL-18) and nitric oxide (NO) involvement in the development of different clinical manifestations of BD as well as to investigate the corticosteroid therapy effect on this production in Algerian patients.
Methods: For this purpose, we evaluated in vivo and ex vivo IL-18, interferon-γ (IFN-γ) levels using ELISA and NO production by the Griess' method in naïve-active and corticosteroid-treated BD patients with different clinical manifestations. Additionally, we assessed CD40/CD40L expression by flow cytometrics assay in these groups of patients.
Results and Discussion: Our results indicate that IL-18 and nitrite levels were higher in naïve-active BD patients. Interestingly, this high production differed according to the clinical manifestations and was associated with an increased risk of mucocutaneous and vascular involvement. Concerning corticosteroid treated-active BD patients, no difference was observed in this production between each clinical subgroup. However, IFN-γ levels increased in all categories of active patients. Interestingly, corticosteroid therapy reduced significantly these inflammatory mediators regardless of the clinical manifestations studied. In addition, the CD40/CD40L expression differed according to the clinical presentations.
Conclusion: Collectively, our results suggest that concomitant high production of IL-18 and NO in naïve-active BD patients is related to an increased risk of mucocutaneous lesions and vascular involvement. Moreover, the relationship between these two inflammatory markers could constitute a predictable tool of BD clinical presentations and an early factor of therapy efficiency.
Databáze: MEDLINE
Externí odkaz: